Want to join the conversation?
$AMGN's target was to launch six new products this year. With the recent approval of Imlygic, a drug for melanoma, $AMGN said that it is now delivering on those six opportunities. $AMGN believes that Repatha, for cardiovascular disease, and Kyprolis, for multiple myeloma, represent significant opportunities for patients and shareholders.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?